Nektar Therapeutics (NKTR) Retained Earnings (2010 - 2026)

Nektar Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$3.8 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 4.33% year-over-year to -$3.8 billion; the TTM figure through Mar 2026 stood at -$3.8 billion (down 4.33% YoY), while the FY2025 annual figure was $17000.0, down 72.13% from the prior year.
• Retained Earnings was -$3.8 billion for Q1 2026 at Nektar Therapeutics, down from $17000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $355000.0 in Q3 2024 to a low of -$3.8 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$2.0 billion across 5 years, with a median of -$3.1 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 105.59% in 2024, then plunged 1049172.39% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$3.2 billion in 2022, then declined by 8.62% to -$3.5 billion in 2023, then soared by 100.0% to $61000.0 in 2024, then tumbled by 72.13% to $17000.0 in 2025, then slumped by 22383570.59% to -$3.8 billion in 2026.
• The last three Retained Earnings figures came in at -$3.8 billion (Q1 2026), $17000.0 (Q4 2025), and -$3.7 billion (Q3 2025), per Business Quant data.